Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
View/ Open
Author
Dowling, Paul
Hayes, Catriona
Ting, Kay Reen
Hameed, Abdul
Meiller, Justine
Clynes, Martin
Clarke, Colin
O’Gorman, Peter
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1186/1471-2164-15-904Metadata
Show full item recordCitation
Dowling, P., C. Hayes, K. R. Ting, A. Hameed, J. Meiller, C. Mitsiades, K. C. Anderson, et al. 2014. “Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.” BMC Genomics 15 (1): 904. doi:10.1186/1471-2164-15-904. http://dx.doi.org/10.1186/1471-2164-15-904.Abstract
Background: Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma patients develop osteolytic bone lesions associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Biomarkers of bone remodelling are used to identify disease characteristics that can help select the optimal management of patients. However, more accurate biomarkers are needed to effectively mirror the dynamics of bone disease activity. Results: A label-free mass spectrometry-based strategy was employed for discovery phase analysis of fractionated patient serum samples associated with no or high bone disease. A number of proteins were identified which were statistically significantly correlated with bone disease, including enzymes, extracellular matrix glycoproteins, and components of the complement system. Conclusions: Enzyme-linked immunosorbent assay of complement C4 and serum paraoxonase/arylesterase 1 indicated that these proteins were associated with high bone disease in a larger independent cohort of patient samples. These biomolecules may therefore be clinically useful in assessing the extent of bone disease. Electronic supplementary material The online version of this article (doi:10.1186/1471-2164-15-904) contains supplementary material, which is available to authorized users.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213504/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347609
Collections
- HMS Scholarly Articles [17921]
Contact administrator regarding this item (to report mistakes or request changes)